Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma

Part of paid clinical trials in Buffalo, New York.

Sponsor
State University of New York at Buffalo
Study ID
NCT04542616
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation — DEVICE
    Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation for the treatment of severe uncontrolled glaucoma.

Study Details

To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.

Key Dates

Start date
Aug 13, 2020
Status verified
Jan 2025
Primary completion
Jul 31, 2024
Completion
Jul 31, 2024

Study Design

Enrollment
80 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Baerveldt 350
    The patients in this arm will receive a Baerveldt 350 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.
  • Active Comparator: Ahmed ClearPath 250
    The patients in this arm will receive an Ahmed ClearPath 250 tube shunt implantation for the treatment of their severe uncontrolled glaucoma.

Primary Outcome Measure

Intraocular Pressure (IOP) [ Time Frame: Baseline, Month 1, Month 3, Month 6, Month 12, Month 24 ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Ira G. Ross Eye InstituteBuffaloNew York14209-

Find similar trials in Buffalo, NY

By condition
Glaucoma
By specialty
Ophthalmology
By research site
The Ira G. Ross Eye Institute· Buffalo, NY

Related Studies